Security key
88032L605
TENAX THERAPEUTICS, INC. - Common Stock, $0.0001 par value per share (TENX)
CUSIP: 88032L605
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Total 13F shares
- 735,804
- Total 13F value
- $10,705,953
- Share change
- +336,559
- SEC-reported price per share
- $14.55
- Number of holders
- 18
- Value change
- +$4,896,941
- Number of buys
- 15
- Number of sells
- 2
- Shares outstanding
- 39,134,398
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
18
Top holders
10
TENX full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q4 2025
TENAX THERAPEUTICS, INC. SEC filings
TENAX THERAPEUTICS, INC. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 88032L605
Recent filing periods:
Ownership snapshot
Top reported holders of TENX - TENAX THERAPEUTICS, INC. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
15/15
Latest evidence
30 Jun 2026
13D/G
13F
Lead comparable stake: 15%
13D/G row: FMR LLC
Showing 1-6 of 15 holder rows.
Quick read
FMR LLC leads the comparable SEC ownership view at 15%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FMR LLC's linked filing trail.
Comparable ownership
Top 5
FMR LLC
15%
Janus Henderson Group Ltd.
10%
BIOTECHNOLOGY VALUE FUND L P
10%
Venrock Healthcare Capital Partne...
9.9%
RTW INVESTMENTS, LP
9.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13D/G
13F
Company
|
15%
|
$42,301,662
3,942,373 shares
|
$0 | 30 Jun 2026 |
| Janus Henderson Group Ltd. |
13F
13D/G
Company · JANUS HENDERSON GROUP PLC
|
10%
from 13D/G
|
$29,065,739
1,815,474 shares
|
— | 31 Mar 2026 |
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
BVF PARTNERS L P/IL
|
10%
|
$28,554,481
1,908,722 shares
|
+$17,062,209 | 31 Mar 2026 |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
9.9%
|
$29,248,371
1,955,105 shares
|
+$18,881,704 | 31 Mar 2026 |
| RTW INVESTMENTS, LP |
13D/G
13F
Company
|
9.9%
|
$27,939,745
1,867,630 shares
|
+$18,201,264 | 31 Mar 2026 |
| Vestal Point Capital, LP |
13D/G
13F
Company
|
9.9%
|
$18,525,720
2,470,096 shares
|
$0 | 30 Sep 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
18
Shares
735,804
Rows available
18
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q4 2025 Across Filers
Q4 2025 holders
48
Q2 2026 holders
18
Holder diff
-30
| Investor | Q4 2025 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q4 2025 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend